Epratuzumab I-131

N/A

Report date: 2025/11/18 17:45:20

Base Information

Drug NameEpratuzumab I-131
Drug Alias NameImmuRAIT-LL2-I-131Monoclonal antibody LL2-I-131Anti-CD22 monoclonal antibody LL2-I-131ImmuRAIT LL2-I-131IMMU LL2-I-131 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionIonising radiation emitters
TargetsCD22
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics IncRepligen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRepligenImmunomedics Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A